First mixed race woman potentially cured of HIV
A female patient, who had leukaemia and HIV has been potentially cured by a stem cell transplant from cord blood, scientists say.
List view / Grid view
A female patient, who had leukaemia and HIV has been potentially cured by a stem cell transplant from cord blood, scientists say.
Medicines which represented significant progress in their therapeutic areas have been listed in the European Medicines Agency's Human Medicines Highlights 2022 report.
GlobalData says CD19 CAR-T agents are expected to treat over 13,000 blood cancer patients annually by 2031, driving sales of Breyanzi and Yescarta.
NICE’s recommendation of Yescarta® means it is the first time patients will be able to access CAR T-cell therapy long-term on the NHS.
A T-cell therapy that targets six viruses commonly contracted by haematology patients after allogeneic stem cell transplantation, offered 95 percent response in a study.
The second-ever patient has been transfused with lab-grown red blood cells in a clinical trial, promising an effective treatment for patients.
Alternative CAR-T and cell therapies increased relapsed multiple myeloma patient survival by 18 months after failed CAR-T, a study found.
A collaboration agreement between Gilead and biopharma company MacroGenics aims to develop MGD024, a bispecific antibody for treatment of blood cancers.
A Phase I trial revealed that Bioheng Biotech’s chimeric antigen receptor (CAR) T-cell therapy drug RD13-01 was safe for use and that it could reduce malignant tumours.
Why are precision medicines important? What challenges face their development and manufacture? Where could they be in 10 years? Discover all this and more in this podcast with Janssen!
New study finds patients receiving chemotherapy have lower COVID-19 antibody levels post-vaccination than patients receiving targeted cancer therapy.
A new study will evaluate COVID-19 vaccines in patients with haematological malignancies who have received cellular therapy.
In this article, European Pharmaceutical Review’s Hannah Balfour discusses how COVID-19 has impacted the pharma industry with regard to cancer clinical trial and treatment disruptions.
AstraZenaca reveals Calquence (acalabrutinib) did not increase the proportion of hospitalised COVID-19 patients who remained alive and free of respiratory failure.
The acquisition will strengthen Merck’s oncology pipeline with VLS-101, an investigational antibody-drug conjugate in trials for haematological malignancies and solid tumours.